× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


× Important note: Due to the end of funding, these reviews are no longer in living mode. We try to update them on a monthly basis.

meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19  

Member of the meta|Evidence galaxy

tutorial video
En     Fr

Our approach

RSS

       
button bars forest bayes pooled summary circles
Treament Trials
Statistically conclusive or suggested result Inconclusive results Uncertain results Safety results
9

suggested 97 % decrease in confirmed COVID (any severity)

statistically conclusive 92 % decrease in symptomatic Covid-19

inconclusive results for: deaths; serious adverse events; adverse events; convulsions/seizures ; disseminated intravascular coagulation ; Guillain-Barré syndrome ; immune thrombocytopenia ; ischemic stroke; Myocardial infarction ; myocarditis; pericarditis ; pulmonary embolism; Transverse myelitis ; venous thromboembolism ; VTE with thrombocytopenia; cerebral venous sinus thrombosis (CVST); arthralgia, grade 3-4; Bell's palsy; hypersensitivity, all terms; lymphadenopathy, grade 3-4; musculoskeletal and connective tissue disorders, any; myalgia, grade 3-4; fever, grade 3-4; local adverse reaction, any, dose 2; local adverse reaction, grade 3-4, dose 2; systemic adverse reaction, any, dose 2; systemic adverse reaction, grade 3-4, dose 2

suggested 95 % decrease in confirmed Covid-19, from 1st dose but the degree if certainty is unassessable

suggested 59 % decrease in death D28 but the degree if certainty is unassessable

suggested 93 % decrease in vaccine efficacy from randomization (ITT) but the degree if certainty is unassessable

statistically conclusive 98 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable

suggested 18 % decrease in appendicitis but with a very low degree of certainty due to critical risk of bias

-
39

suggested 83 % decrease in confirmed Covid-19, from 1st dose

suggested 90 % decrease in confirmed COVID (any severity)

suggested 71 % decrease in vaccine efficacy after dose 1 (and before dose 2)

inconclusive results for: deaths; cerebrovascular thromboembolic events; related AE (TRAE); related SAE (TRSAE); serious adverse events; adverse events; arrhythmia; Arthritis or arthropathy ; convulsions/seizures ; deep vein thrombosis; disseminated intravascular coagulation ; Guillain-Barré syndrome ; Herpes simplex infection ; herpes zoster infection ; immune thrombocytopenia ; intracranial hemorrhage ; ischemic stroke; life-threatening SAE; Myocardial infarction ; myocarditis; neutropenia ; paresthesia ; pericarditis ; pulmonary embolism; severe adverse events; thrombocytopenia ; Transverse myelitis ; uveitis ; venous thromboembolism ; VTE with thrombocytopenia; cerebral venous sinus thrombosis (CVST); appendicitis; Bell's palsy; hypersensitivity, all terms; immediate allergic reaction; lymphadenopathy, any; musculoskeletal and connective tissue disorders, any; myelitis; local adverse reaction, any, dose 1; local adverse reaction, any, dose 2; systemic adverse reaction, any, dose 1; systemic adverse reaction, any, dose 2

suggested 91 % decrease in 6 months symptomatic COVID but the degree if certainty is unassessable

suggested 82 % decrease in vaccine efficacy from randomization (ITT) but the degree if certainty is unassessable

suggested 92 % decrease in hospitalization but the degree if certainty is unassessable

statistically conclusive 94 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable

suggested 97 % decrease in 6 months severe COVID-19 but the degree if certainty is unassessable

suggested 77 % decrease in asymptomatic COVID case but the degree if certainty is unassessable

suggested 83 % decrease in infection (PCR positive symptomatic or not) but the degree if certainty is unassessable

suggested 94 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable

suggested 47 % decrease in transmission (symptomatic confirmed COVID19) but with a low degree of certainty due to high risk of bias

suggested 56 % decrease in acute kidney injury but the degree if certainty is unassessable

suggested 21 % decrease in Anemia but the degree if certainty is unassessable

-
19

statistically conclusive 71 % decrease in symptomatic Covid-19

suggested 85 % decrease in vaccine efficacy after dose 1 (and before dose 2)

inconclusive results for: deaths; severe COVID-19 occurrence; serious adverse events; adverse events; ATE (Myocardial infarction or ischemic stroke); ATE with thrombocytopenia; deep vein thrombosis; disseminated intravascular coagulation ; Guillain-Barré syndrome ; immune thrombocytopenia ; intracranial hemorrhage ; ischemic stroke; Myocardial infarction ; pulmonary embolism; serious adverse events (SAE), any; splanchnic vein thrombosis (SVT); stroke (non-specific, hemorrhagic, and ischemic); stroke with thrombocytopenia; thrombocytopenia ; venous thromboembolism ; VTE with thrombocytopenia; cerebral venous sinus thrombosis (CVST); Bell's palsy; immediate allergic reaction; multiple sclerosis; myelitis; Potential Immune Gastrointestinal disorders; Potential Immune Musculoskeletal disorders; Potential Immune Neuroinflammatory disorders; Potential Immune Skin disorders; Potential Immune Vasculitides; Thromboembolic events

suggested 67 % decrease in asymptomatic COVID case but the degree if certainty is unassessable

suggested 56 % decrease in infection (PCR positive symptomatic or not) but the degree if certainty is unassessable

suggested 48 % decrease in transmission (symptomatic confirmed COVID19) but with a low degree of certainty due to high risk of bias

-
9 noneinconclusive results for: hospitalization; ATE (Myocardial infarction or ischemic stroke); deep vein thrombosis; Guillain-Barré syndrome ; intracranial hemorrhage ; ischemic stroke; Myocardial infarction ; myocarditis; pericarditis ; pulmonary embolism; venous thromboembolism ; cerebral venous sinus thrombosis (CVST); appendicitis; Bell's palsy

suggested 81 % decrease in deaths but the degree if certainty is unassessable

statistically conclusive 67 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable

suggested 77 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable

-

Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant

149
treatments 		  718
studies with results 		  1743
studies screend 		  1629
references

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N), Université de Lyon (UdL/Idex), and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

     

- About - Our approach - Credits - RSS Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons